The return of elective procedure volumes, new product offerings and a busy first quarter of acquisitions all supported healthy growth for the Extremities Market
While growth drivers varied for specific companies in Q122, the return of elective procedure volumes helped drive double-digit growth for several market players. Stryker*, the Extremities Market leader, benefited from the return of elective procedures in the US. Its US Foot & Ankle and Upper Extremities business segments contributed to the Company’s US Trauma & Extremities growth during the quarter. Stryker also noted during its earnings call that ...
Among the many topics covered in detail in our comprehensive Q122 Extremities Market Recap* are:
- Complete Q122 Extremities Market Overview and Highlights
- SmartTRAK's Expert Analysis and Insights
- Extremities News, Revenues, Data, Charts and Shares
- Double-Digit Gains Amidst Returning Procedure Volumes
- New Products/New Offerings
- Mergers & Acquisitions
- Q122 Regulatory Highlights
Deals in the Extremities space outpaced 2021 with three acquisitions completed in the first quarter of 2022 and a strategic partnership. Acquisitions were completed in each month of the quarter. In January, Paragon 28 acquired ...
*The entire unedited article and these links can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below. 
SmartTRAK has recently expanded it's coverage to include five new modules, including Pediatric Extremities and Trauma. Click to see details of all the exciting new additions to the SmartTRAK platform in 2021.
